drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Fully human anti-CD20 IgG1 monoclonal antibody (brand: Kesimpta) administered subcutaneously; binds a membrane-proximal CD20 epitope and depletes CD20+ B cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis; spares stem cells and plasma cells and reduces antigen presentation and pro-inflammatory cytokines (e.g., IL-6, GM-CSF).
nci_thesaurus_concept_id
C66952
nci_thesaurus_preferred_term
Ofatumumab
nci_thesaurus_definition
A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.
drug_mesh_term
Ofatumumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Fully human IgG1 anti‑CD20 monoclonal antibody that binds a membrane‑proximal CD20 epitope on B cells and depletes CD20+ B cells via complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis; spares stem cells and plasma cells, reducing antigen presentation and pro‑inflammatory cytokines.
drug_name
Ofatumumab
nct_id_drug_ref
NCT06668324